Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-30 · accession 0001883850-22-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-01 | 2022-03-30 | REGN | Bassler Bonnie L | Dir | M - OptEx | $380.95 | +1,240 | 2,322 | +115% | +$472.4K |
| D | 2022-04-01 | 2022-03-30 | REGN | Bassler Bonnie L | Dir | S - Sale+OE | $700.00 | -1,240 | 1,082 | -53% | -$868.0K |
| D | 2022-04-01 | 2022-03-30 | REGN | Bassler Bonnie L | Dir | M - OptEx | $0.00 | -1,240 | 6,199 | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-30 | M | A | 1,240 | $380.95 | 2,322 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-30 | S | D | 1,240 | $700.00 | 1,082 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-30 | M | D | 1,240 | $0.00 | 6,199 | D | $380.95 · — to 2028-01-02 | 1,240 Common Stock | (F2) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |